Aktie A2QPPG ISLEWORTH HEALTHCARE ACQUISITION CORP.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Isleworth Healthcare Acquisition Corp.

Aktien

A2QPPG

US46468P1021

ISLE

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
ISLEWORTH HEALTHCARE ACQUISITION CORP. : Other Events, Financial Statements and Exhibits (form 8-K)
Isleworth Healthcare Acquisition to Dissolve, Delist After Failing to Combine Business by Sept. 1
Isleworth Healthcare Acquisition Corp.(NasdaqCM:ISLE) dropped from NASDAQ Composite Index
Isleworth Healthcare Acquisition Corp. Announces Cancellation of Special Meeting of Shareholders, Redemption of Public Shares and Subsequent Dissolution
ISLEWORTH HEALTHCARE ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Isleworth Healthcare Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Blank Check Firm Isleworth Healthcare Acquisition, Cytovia Scrap Merger Deal
ISLEWORTH AND CYTOVIA TERMINATE MERGER AGREEMENT
Isleworth Healthcare Acquisition : AND CYTOVIA TERMINATE MERGER AGREEMENT - Form 8-K
ISLEWORTH HEALTHCARE ACQUISITION CORP. : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
Cytovia Therapeutics, Inc. cancelled the acquisition of Isleworth Healthcare Acquisition Corp. from Isleworth Healthcare Sponsor I, LLC and others in a reverse merger transaction.
ISLEWORTH HEALTHCARE ACQUISITION CORP. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
ISLEWORTH HEALTHCARE ACQUISITION CORP. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
Cytovia Therapeutics presents antitumor activity of its CD38-Targeting Flex-NK™ Cell Engager antibody at EHA 2022 Congress
Isleworth Healthcare Acquisition : Cytovia Therapeutics Appoints Luca Scavo as Chief Financial Officer and James Priour as Chief Product Officer - Form 8-K
ISLEWORTH HEALTHCARE ACQUISITION CORP. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Isleworth Healthcare Acquisition : Quarterly Report (Form 10-Q)
Isleworth Healthcare Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022
ISLEWORTH HEALTHCARE ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Cytovia Therapeutics to Present In Vivo Multiple Myeloma Data of its CD38-Targeting Flex-NK™ Cell Engager at EHA 2022 Congress
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2QPPG Aktie
  4. Nachrichten Isleworth Healthcare Acquisition Corp.
  5. Andere Sprachen